Wockhardt shares hit 52-week high after US FDA approval for Zaynich antibiotic drug; stock up 60% in one month

Wockhardt share prices surged more than 19% to hit its 52-week high level during the early market hours on Monday, June 1, after the pharmaceutical company secured approval from the US Food and Drug Administration (FDA) for its new antibiotic drug named Zaynich.

Shares of Wockhardt surged 19.2% to hit its 52-week high of ₹2,422.30 on June 1, 2026, compared to ₹2,031.40 at the previous market close. The 52-week low was at ₹1,086.70 on March 23, 2026, according to NSE data.

As per the NSE filing, Wockhardt disclosed that the Zaynich drug is a novel intravenous antibiotic used for the treatment of adults with complicated urinary tract infections.

“The U.S. Food and Drug Administration (FDA) has approved ZAYNICH™ (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative pathogens,” the company informed the stock exchanges.

The company also disclosed that in America, more than 2.8 million antimicrobial-resistant infection cases occur every year, resulting in more than 35,000 deaths. The new drug aims to work against the infection and deliver a clinical cure.

“The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens. The FDA approval of ZAYNICHTM is a monumental step forward in validating a new option for these underserved populations,” said Dennis Deruelle, MD, FHM, Chief Medical Officer at Wockhardt.

Wockhardt share up 60% in one month

Wockhardt shares have delivered more than 260% returns on their investment in the last five years, over 1,228% gains in the last three years, and more than 52% returns in the past one year, according to NSE data.

So far in 2026, the company’s stock has risen 57% in 2026, and gained over 60% returns in the past one month. Wockhardt shares were trading 36% higher over the last five trading sessions on the Indian stock market.

The pharma company’s market capitalisation (m-cap) was at ₹36,809 crore as of Monday’s trading session.

Last week, Wockhardt shares rallied 17% after the company was granted an import and marketing authorisation for the urinary tract infection (UTI) antibiotic from the Central Drugs Standard Control Organisation (CDSCO).

The FDA approval comes after the company successfully turned around its losses into profits, posting a ₹166 crore net profit in the January to March quarter of the year ended 2025-26, against a net loss of ₹25 crore in the same period a year ago.

The pharma company’s revenue from core operations advanced 30% to ₹965 crore during the fourth quarter, compared to ₹743 crore in the same period a year ago.

On the profitability scale, the company’s operational level EBITDA, or earnings before interest, tax, depreciation, and amortisation expanded 147% to 196 crore as of March 31, 2026, from earlier ₹79 crore levels.